Board of Directors


Horst G. Zerbe, Ph.D., President and CEO.

J. Bernard Boudreau, QC, PC, has a distinguished record as a lawyer, businessman and public figure. He founded and served as the senior partner of a law firm in Nova Scotia and was appointed Queen’s Counsel in 1985. He was first elected to the provincial legislature of Nova Scotia in 1988, where he served in various senior cabinet positions including Minister of Finance and Minister of Health.

In 1999, the Prime Minister of Canada appointed Mr. Boudreau to the positions of Leader of the Government in the Senate of Canada and the Federal Minister responsible for Nova Scotia. The legislative highlight of his career in the Senate came when he led the fight in that Chamber to pass the Clarity Act, working in close cooperation with the Honorable Stéphane Dion and Prime Minister Chrétien.

In 2001, he resumed his private career as President and CEO of Radcliffe Consulting and Investment Ltd. in Halifax, Nova Scotia. In March 2001, he was appointed a Director of Export Development Canada (“EDC”), serving as Chairman of the Pension and Human Resource Committees of that Board. He also serves on the Board of Directors of a number of other public and private corporations. Most recently he has agreed to serve as Chair of the Board of Directors of the Eman Bank of Canada.

Rajiv Khosla RPh, PhD, MBA was recently named President, Chief Executive Officer and a member of the board of directors of Orasi Medical, a leading provider of clinical neurophysiology biomarkers, focused on the industrialization and standardization of magnetoencephalography (MEG) in central nervous system drug and therapeutic device development. In January 2011, Dr. Khosla founded CEUTEC LLC, a private company that offers a full-service of business development activities to Biotech, Specialty Pharma and Venture Capital/Private Equity Firms. From September 2005 to December 2010, Dr. Khosla was Vice President of Business Development at Biovail Corporation, a Canadian pharmaceutical company operating internationally. During his tenure at Biovail, Dr. Khosla successfully led the transaction process for over 75 deal opportunities in a variety of therapeutic areas, including the central nervous system, dermatology, women's health, cardiovascular and gastrointestinal, drug delivery, orphan drugs, generics and pipeline partnerships. From 2003 to 2005, Dr. Khosla held the position of Vice President and General Manager, Pharmaceutical, of Sensient Technologies. From 1998 to 2003, Dr. Khosla served as Senior Business Director, Healthcare at ICI Group, where he managed a new worldwide healthcare business.

Dr. Khosla possesses a Ph.D. in pharmaceutical science, with a thesis on Oral Drug Delivery Technology, which he completed in 1987. Additionally, Dr. Khosla holds an Executive MBA from the Henley Business School in England, a Bachelor of Pharmacy (Honours) from the University of Nottingham, England and is also a registered pharmacist in the UK.

John S. Marinucci, C.A., ICD.D, H.R.C.C.C. is the former President and Chief Executive Officer of New Flyer Industries Inc. During his seven year tenure with New Flyer, Mr. Marinucci successfully restructured its manufacturing operations and the aftermarket services business transforming New Flyer into the North American leader in the heavy-duty transit market. Under his leadership, New Flyer completed its IPO in August 2005 and successfully completed secondary offerings in July 2007 and April 2008. Previously, he served as President and Chief Operating Officer for National Steel Car and is a former President of the Canadian Association of Railway Suppliers. Mr. Marinucci currently serves on the board of directors for New Flyer, CWB Group, Seaport Intermodal Inc., and Pillar5 Pharma.

Bernd J. Melchers, business economist, is a 30-year veteran of the pharmaceutical and health care industry with extensive experience in corporate financial management. Most recently, he was Managing Director of 3M Dyneon Holding GmbH, Germany and Global Chief Financial Officer of the world wide operating 3M Dyneon Group, a subsidiary of 3M Corporation headquartered in Minnesota. Previously, he served as the European Controller of 3M Medical Markets at the 3M Europe Headquarter located in Brussels, Belgium. Prior to this he held various senior management positions at the Medical-Surgical Division of 3M in St. Paul, Minnesota, at 3M Health Care Products, Germany, and 3M Pharmaceutical Products, Germany.

Ian Troup, B.Sc. has more than 40 years of experience in the pharmaceutical industry, most recently serving as President and Chief Operating Officer of Upsher-Smith Laboratories, a privately held generic pharmaceutical company, prior to which he was President of Schwarz Pharma USA. He is currently an active board member of several Minneapolis-based businesses including: Medisyn Technologies, a privately funded corporation involved in computer based topological drug design and TwinWest PAC, a political action committee helping Minnesota businesses gain local, state and federal access to political officials.